Literature DB >> 18416450

Anti-HIV adaptive immunity: determinants for viral persistence.

Hiroyuki Yamamoto1, Tetsuro Matano.   

Abstract

The immense difficulty in primary control of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infection by adaptive immune responses has been a topic of exceptional importance. CD8+ cytotoxic T lymphocytes (CTLs) do play a central role in primary resolution of viremia, but their potency in viral control is generally constrained in the natural courses of HIV/SIV infections. The overall repertoire of CTLs is dependent on both the host and the virus genetic polymorphisms, and the potency of each individual CTL is affected by immunological and virological determinants. HIV/SIV infections lack early appearance of neutralising antibodies (NAbs), and our recent finding has suggested a possibility of their absence contributing to diminished virus-specific CD4+ T-cell responses leading to failure in primary viral control. Extrapolations from studies in macaque models of SIV infection and analyses of the cohorts of HIV control in humans have to date delineated the numerous requirements for attainment of viral control. Understanding of the individual components of adaptive immune responses and their optimal concert required for HIV/SIV control would contribute to development of an effective AIDS vaccine. Here, we discuss current insights into CTLs and NAbs, and speculate their possible protective mechanism against establishment of persistent HIV/SIV infection. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18416450     DOI: 10.1002/rmv.577

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  7 in total

1.  Broadening CD4+ and CD8+ T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes.

Authors:  Jonathan Filskov; Marianne Mikkelsen; Paul R Hansen; Jan P Christensen; Allan R Thomsen; Peter Andersen; Jens Bukh; Else Marie Agger
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

Review 2.  HIV vaccine development: an exploratory review of the trials and tribulations.

Authors:  David Rhys Alchin
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

Review 3.  Chronic alcohol abuse and HIV disease progression: studies with the non-human primate model.

Authors:  Angela M Amedee; Whitney A Nichols; Spencer Robichaux; Gregory J Bagby; Steve Nelson
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

4.  Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody.

Authors:  Ilnour Ourmanov; Takeo Kuwata; Robert Goeken; Simoy Goldstein; Ranjani Iyengar; Alicia Buckler-White; Bernard Lafont; Vanessa M Hirsch
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

Review 5.  HIV-1 neuroimmunity in the era of antiretroviral therapy.

Authors:  Stephanie D Kraft-Terry; Andrew R Stothert; Shilpa Buch; Howard E Gendelman
Journal:  Neurobiol Dis       Date:  2010-01-04       Impact factor: 5.996

6.  Association between specific HIV-1 Env traits and virologic control in vivo.

Authors:  Beda Joos; Philip Rieder; Marek Fischer; Herbert Kuster; Peter Rusert; Alexandra Trkola; Satish K Pillai; Joseph K Wong; Rainer Weber; Huldrych F Günthard
Journal:  Infect Genet Evol       Date:  2009-06-11       Impact factor: 3.342

7.  Vaccination with Human Induced Pluripotent Stem Cells Creates an Antigen-Specific Immune Response Against HIV-1 gp160.

Authors:  Shinji Yoshizaki; Mayuko Nishi; Asami Kondo; Yoshitsugu Kojima; Naoki Yamamoto; Akihide Ryo
Journal:  Front Microbiol       Date:  2011-02-22       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.